RNAI TECHNOLOGY MARKET ANALYSIS

Rnai Technology Market Size and Trends

Global RNAi technology market is estimated to be valued at USD 2.70 Bn in 2024 and is expected to reach USD 7.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.8% from 2024 to 2031.

To learn more about this report, Request sample copy

The development of improved RNAi delivery mechanisms and next generation targeting capabilities can boost demand. More pharmaceutical companies are leveraging RNAi for drug discovery and developing RNAi therapeutics for genetic disorders, oncology, and infectious diseases. Increased funding for R&D and growing clinical trial approvals are can  provide opportunities for the market growth. Continued expansion of CRISPR and other gene editing technologies hamper RNAi technology adoption in the future.

Growing demand for RNAi technology due to increased R&D efforts

Rising demand for RNAi technology due to increased research and development efforts by pharmaceutical companies and research institutions can drive the market growth. RNAi refers to the process of gene silencing through the introduction of double-stranded RNA molecules into the cell, which helps in selectively turning off specific genes. This mechanism is being actively explored by drug developers for its potential to develop powerful new therapies for various diseases. Many biotech companies and academic research labs across the globe are demonstrating the broad potential of RNAi technology through various preclinical and clinical research studies. In November 2020, Alnylam Pharmaceuticals, Inc. introduced new Value-based Agreements (VBAs) aimed at enhancing patient access to givosiran, thus, strengthening the company's position in RNAi therapeutics and bolstering its business prospects. In December 2021, Novartis AG obtained approval from the U.S. Food and Drug Administration for Leqvio, the first and only small interfering RNA (siRNA) therapy that  is designed to reduce low-density lipoprotein levels with just two doses per year: an initial dose followed by another at three months.

To learn more about this report, Request sample copy

Advances in Delivery Technologies Opening New Avenues

One of the major bottlenecks limiting the clinical potential of RNAi therapeutics has been the lack of efficient and safe delivery systems. The highly labile nature of nucleic acid drugs and challenges associated with their in vivo delivery to target sites requires innovative formulation and design strategies. Novel delivery technologies such as ligand-conjugated nanoparticles, exosome-mimetic vesicles and cell-penetrating peptides can enhance the cellular uptake and protection of RNAi payloads. Advancements are also being made in modulating biodistribution through tissue-targeting ligands and optimizing pharmacokinetic profiles. Recent delivery platforms enable targeting of RNAi molecules to specific organs, cell types and subcellular locations based on pathological needs. This high precision delivery promises to augment therapeutic indices while reducing adverse effects. As more biocompatible carriers successfully navigate clinical translation, these will facilitate the development of RNAi drugs for diverse pathological conditions including those traditionally considered difficult to drug.